474707-20-5

Basic information

• Product Name: Quinoline, 6-bromo-4-(4-morpholinyl)-
• Synonyms: 4-(6-Bromo-4-quinolyl)-morpholine;4-(6-bromoquinolin-4-yl)morpholine;6-bromo-4-morpholin-4-yl-quinoline;4-(6-bromo-4-quinolyl)morpholine
• CAS NO: 474707-20-5
• Molecular Formula: C13H13BrN2O
• Molecular Weight: 293.15900
• Mol File: 474707-20-5.mol
• Article Data: 9

Chemical Properties

• Melting Point: 72 - 73 °C
• CAS DataBase Reference: Quinoline, 6-bromo-4-(4-morpholinyl)-(CAS DataBase Reference)
• NIST Chemistry Reference: Quinoline, 6-bromo-4-(4-morpholinyl)-(474707-20-5)
• EPA Substance Registry System: Quinoline, 6-bromo-4-(4-morpholinyl)-(474707-20-5)

Safety Data

• Hazardous Substances Data: 474707-20-5(Hazardous Substances Data)

Upstream product

• 145369-94-4 6-bromoquinolin-4-ol 
• 110-91-8 morpholine 
• 65340-70-7 6-bromo-4-chloroquinoline 

Downstream Products

• 1201842-32-1 2,6-dichloro-N-(2-chloro-5-(4-(4-morpholinyl)-6-quinolinyl)-3-pyridinyl)benzenesulfonamide 
• 1201842-28-5 N-(2-chloro-5-(4-(4-morpholinyl)-6-quinolinyl)-3-pyridinyl)-2-fluorobenzenesulfonamide 
• 1201841-60-2 N-(2-chloro-5-(4-morpholinoquinolin-6-yl)pyridin-3-yl)-4-fluorobenzenesulfonamide 
• 1404227-77-5 3-(2,4-difluorophenylsulfonamino)-2-methoxy-5-(4-morpholinoquinolin-6-yl)benzamide 
• 1404227-75-3 3-(4-fluorophenylsulfonamino)-2-methoxy-5-(4-morpholinoquinolin-6-yl)benzamide 

Relevant articles and documents

DERIVATIVES OF QUINOLINE AS INHIBITORS OF DYRK1A AND/OR DYRK1B KINASES

The present invention relates to the compound of formula (I) and salts, stereoisomers, tautomers or N-oxides thereof. The present invention is further concerned with the use of such a compound or salt, stereoisomer, tautomer or N-oxide thereof as medicament and a pharmaceutical composition comprising said compound.

Fused ring compound and preparation method, application and intermediate compound thereof

The invention relates to a fused ring compound and a preparation method, application and intermediate compound thereof. The fused ring compound can be used as an inhibitor of phosphatidylinositol 3-kinase.

Discovery of 2-methoxy-3-phenylsulfonamino-5-(quinazolin-6-yl or quinolin-6-yl)benzamides as novel PI3K inhibitors and anticancer agents by bioisostere

2-Substituted-3-sulfonamino-5-(quinazolin-6-yl or quinolin-6-yl)benzamides have been proposed as novel structures of PI3K inhibitors and anticancer agents based on bioisostere. In the present study, 2-substituted-3-sulfonamino-5-(4- morpholinoquinazolin-6-yl)benzamides and 2-methoxy-3-sulfonamino-5-(4- morpholinoquinolin-6-yl)benzamides were synthesized. Their antiproliferative activities in vitro were evaluated via MTT assay against four human cancer cell lines, including A549, HCT-116, U-87 MG and KB. The SAR of the title compounds was preliminarily discussed. Compound 1a with potent antiproliferative activity was tested for its inhibitory activity against PI3K and mTOR and its effect on the AKT and p-AKT473. The anticancer effect of 1a was evaluated in established nude mice U-87 MG xenograft model. The results suggest that compound 1a can significantly inhibit PI3K/AKT/mTOR pathway and tumor growth. These findings strongly support the assumption that title compounds are potent PI3K inhibitors and anticancer agents.